Literature DB >> 20002302

Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C.

A Birerdinc1, A Afendy, M Stepanova, I Younossi, G Manyam, A Baranova, Z M Younossi.   

Abstract

Chronic hepatitis C (CH-C) is among the most common causes of chronic liver disease. Approximately 50% of patients with CH-C treated with pegylated interferon-α and ribavirin (PEG-IFN-α + RBV) achieve a sustained virological response (SVR). Several factors such as genotype 1, African American (AA) race, obesity and the absence of an early virological response (EVR) are associated with low SVR. This study elucidates molecular pathways deregulated in patients with CH-C with negative predictors of response to antiviral therapy. Sixty-eight patients with CH-C who underwent a full course of treatment with PEG-IFN-α + RBV were included in the study. Pretreatment blood samples were collected in PAXgene™ RNA tubes. EVR, complete EVR (cEVR), and SVR rates were 76%, 57% and 41%, respectively. Total RNA was extracted from pretreatment peripheral blood mononuclear cells, quantified and used for one-step RT-PCR to profile 154 mRNAs. The expression of mRNAs was normalized with six 'housekeeping' genes. Differentially expressed genes were separated into up and downregulated gene lists according to the presence or absence of a risk factor and subjected to KEGG Pathway Painter which allows high-throughput visualization of the pathway-specific changes in expression profiles. The genes were consolidated into the networks associated with known predictors of response. Before treatment, various genes associated with core components of the JAK/STAT pathway were activated in the cohorts least likely to achieve SVR. Genes related to focal adhesion and TGF-β pathways were activated in some patients with negative predictors of response. Pathway-centred analysis of gene expression profiles from treated patients with CH-C points to the Janus kinase-signal transducers and activators of transcription signalling cascade as the major pathogenetic component responsible for not achieving SVR. In addition, focal adhesion and TGF-β pathways are associated with some predictors of response.
© 2009 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20002302     DOI: 10.1111/j.1365-2893.2009.01235.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  5 in total

1.  KPP: KEGG Pathway Painter.

Authors:  Ganiraju Manyam; Aybike Birerdinc; Ancha Baranova
Journal:  BMC Syst Biol       Date:  2015-04-15

2.  Negative regulation of hepatitis C virus specific immunity is highly heterogeneous and modulated by pegylated interferon-alpha/ribavirin therapy.

Authors:  Mark A A Claassen; Robert J de Knegt; Duygu Turgut; Zwier M A Groothuismink; Harry L A Janssen; André Boonstra
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

3.  Gene expression profiling of dendritic cells in different physiological stages under Cordyceps sinensis treatment.

Authors:  Chia-Yang Li; Chi-Shiun Chiang; Wei-Chung Cheng; Shu-Chi Wang; Hung-Tsu Cheng; Chaang-Ray Chen; Wun-Yi Shu; Min-Lung Tsai; Ruey-Shyang Hseu; Cheng-Wei Chang; Chao-Ying Huang; Shih-Hua Fang; Ian C Hsu
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

4.  The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.

Authors:  Zobair M Younossi; Aybike Birerdinc; Mike Estep; Maria Stepanova; Arian Afendy; Ancha Baranova
Journal:  J Transl Med       Date:  2012-02-07       Impact factor: 5.531

Review 5.  Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy.

Authors:  Bassem Refaat; Ahmed Mohamed Ashshi; Adel Galal El-Shemi; Esam Azhar
Journal:  Mediators Inflamm       Date:  2015-04-19       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.